On April 16, Johnson & Johnson reported first-quarter earnings of $2.71 per share, beating FactSet's consensus of $2.66.
One of the biggest problems for healthcare firm Johnson & Johnson (NYSE:JNJ) in the last decade or so has been talc. This ...
Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen a variety of use cases ...
Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall.
The "Diphtheria - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.Diphtheria Pipeline Insight, 2024 report outlays comprehensive insights of present ...
Apollo Global Management (NYSE:APO) – Sony Pictures Entertainment and Apollo Global Management are in discussions for a joint ...
Johnson & Johnson's (JNJ) talc-based baby powder did not cause cancer in a Florida woman, according to a recent jury verdict.
Johnson & Johnson's talc-based baby powder was not the cause of a woman's death from ovarian cancer, a Florida jury decided in a case brought against the manufacturer. Separately, Eli Lilly warned ...